Sector: health
Conviction from: NASDAQ
A biopharmaceutical company developing and commercializing therapies for rare and serious diseases, including pulmonary and inflammatory conditions.
4 tracked filer(s) hold this · 1 opened, 0 added, 2 trimmed in 31-MAR-2026
Aggregate 13FScore 56 — mean of 4 scored holder(s) · buyers (new/add) avg 55. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Bridgewater | 55 | New buy | 295,579 | $48,333,078 | 0.2% |
| Ancora | 42 | Holds (flat) | 214 | $34,993 | 0.0% |
| Darwin Global Management, Ltd. (auto-surfaced) | 34 | Trimmed -20% | 16,805,184 | $2,576,570,811 | 68.3% |
| Stanley Druckenmiller / Duquesne | 91 | Trimmed -22% | 1,154,090 | $188,717 | 5.6% |
Beyond 13F — activists, insiders, politicians & research
1 disclosed trade(s) by 1 filer(s).
4 disclosed trade(s) by 1 filer(s).
| Trade date | Who | Type | Amount | |
|---|
| 2026-07-01 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |